Physician profile
Samuel Dubrow
NPI 1639349590
$34,236.07
in general payments reported to CMS, 2019-2025
10 companies · $559 in 2025
The $559 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $22.86 · 2021: $15K · 2022: $1,991 · 2023: $2,659 · 2024: $2,007 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,300 · Travel and Lodging: $1,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,299.63 |
| Travel and Lodging | $1,925.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $30,750.53 | 2019-2025 | Arthrex |
| Conetic Solutions, INC. | $1,259.24 | 2021-2025 | |
| Encore Medical, LP | $1,012.85 | 2019 | |
| Stryker Corporation | $957.37 | 2021-2025 | Prophecy, Axsos, Augment Injectable |
| Depuy Synthes Sales INC. | $122.01 | 2025 | Na |
| Catalyst Orthoscience | $46.54 | 2024 | Catalyst Csr Shoulder System |
| Rsw Medical Company, INC. | $30.19 | 2019 | |
| Smith+Nephew, INC. | $22.86 | 2020 | |
| Si-Bone, INC. | $18.49 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Dubrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.